Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04CJN
|
|||
| Former ID |
DIB007856
|
|||
| Drug Name |
CTP-298
|
|||
| Synonyms |
C-10276; CTP-518; Deuterated atazanavir isotopologs (HIV infection), CoNCERT/GSK
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
CoNCERT Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01458769) Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz. U.S. National Institutes of Health. | |||
| REF 2 | Avanir Licenses Concert's Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal. Vol 2012 Issue 3 Page(38). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.